Inozyme Pharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Inozyme Pharma, Inc. announced the postponement of its 2025 Annual Meeting of Stockholders due to its pending acquisition by BioMarin Pharmaceutical Inc.
Inozyme Pharma will hold its annual stockholders meeting virtually on June 25, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
Inozyme Pharma announces its 2025 annual meeting of stockholders to be held virtually on June 25, 2025, featuring the election of directors and ratification of the company's accounting firm.
Inozyme Pharma will hold its annual stockholders meeting on June 18, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent auditor.
Inozyme Pharma will hold its 2024 annual meeting of stockholders virtually on June 18, 2024, to vote on the election of directors and ratification of the company's independent auditor.